Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Completed · Phase 3 · Has a placebo group

Conditions studied: Facial Rhytides, Crow's Feet Lines, Glabellar Lines

In brief

This study will evaluate the safety and efficacy of botulinum toxin type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for patients who successfully completed Study 191622-099.

Key facts

Study ID

NCT01224015

Run by

Allergan

People needed

684

Starts

2011-05-01

Expected to finish

2012-02-01

Last updated by the study team

2014-02-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Successfully completed Study 191622-099

You may not qualify if…

• Known immunization or hypersensitivity to botulinum toxin of any serotype
• Anticipated need for treatment with botulinum toxin of any serotype during the study (except for study treatment)
• Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis
• Anticipated need for surgery or hospitalization during the study

Where it is running

• Study site — Newport Beach, California, United States
• Study site — Vancouver, British Columbia, Canada
• Study site — Antibes, France
• Study site — Berlin, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.